Abiopharma

ANIXA BIOSCIENCES INC (ANIX)

Symbol	ANIX
Name	ANIXA BIOSCIENCES INC
Sector	HEALTH CARE
Region	North America
Industry	Pharmaceutical Preparations
Address	3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA 95118
Telephone	408-708-9808
Fax	—
Email	—
Website	https://www.anixa.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0000715446
Description	Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixas therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Companys vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against retired proteins that have been found to be expressed in certain forms of cancer. Additional info from NASDAQ: Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixas therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Companys vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.

2026-07-21 14:23

Director KUMAR AMIT 🟢 acquired 5.0K shares of Anixa Biosciences Inc (ANIX) at $3.46 Transaction Date: Jul 20, 2026 | Filing ID: 034027

2026-07-20 22:19

Director Titterton Lewis H jr 🟢 acquired 12.0K shares of Anixa Biosciences Inc (ANIX) at $3.47 Transaction Date: Jul 20, 2026 | Filing ID: 033949

2026-07-16 13:00

Director Titterton Lewis H jr 🟢 acquired 2.8K shares of Anixa Biosciences Inc (ANIX) at $3.28 Transaction Date: Jul 15, 2026 | Filing ID: 033461

2026-07-14 12:33

Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology

2026-07-06 12:30

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

2026-06-29 12:45

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

2026-06-26 13:10

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium

2026-06-17 15:21

Director Titterton Lewis H jr 🟢 acquired 2.8K shares of Anixa Biosciences Inc (ANIX) at $2.64 Transaction Date: Jun 16, 2026 | Filing ID: 029030

2026-06-16 13:00

Director KUMAR AMIT 🟢 acquired 21.0K shares of Anixa Biosciences Inc (ANIX) at $2.50 Transaction Date: Jun 12, 2026 | Filing ID: 028827

2026-06-11 13:05

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT05316129	Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent O…	Phase1	Ovarian Cancer	Recruiting	2022-04-28	2029-05-01	ClinicalTrials.gov

Total clinical trials: 1

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Zymosan	Other	Phase EARLY_PHASE1	Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer	ACTIVE_NOT_RECRUITING	NCT04674306
α-lactalbumin vaccine	Other	Phase EARLY_PHASE1	Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer	ACTIVE_NOT_RECRUITING	NCT04674306
Follicle Stimulating Hormone Receptor T Cells	Other	Phase PHASE1	Ovarian Cancer	RECRUITING	NCT05316129
Follicle Stimulating Hormone Receptor T Cells	DRUG	Phase PHASE1	Ovarian Cancer	RECRUITING	NCT05316129
Zymosan	BIOLOGICAL	Phase EARLY_PHASE1	Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer	ACTIVE_NOT_RECRUITING	NCT04674306
α-lactalbumin vaccine	BIOLOGICAL	Phase EARLY_PHASE1	Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer	ACTIVE_NOT_RECRUITING	NCT04674306

Total products: 6